RetiSpec is working on a non-invasive, cost-effective, and early-stage diagnostic procedure that can detect Alzheimer’s through the retina. Cubert, in turn, develops and designs the hyperspectral cameras required for this technology. As a result, an annual visit to the ophthalmologist could soon offer far more than just a vision test.
One major advantage: Retinal examinations are already part of everyday medical practice, especially among older adults. The technology developed by Cubert and RetiSpec integrates seamlessly into existing workflows—without additional effort or lengthy examinations. For patients, this means just a few short flashes of light instead of long and uncomfortable scanning procedures.
Why Early Detection Matters
Modern UAVs can safely fly over dangerous or inaccessible areas while collecting high-resolution spectral data—without risking personnel on the ground. The mobility and readiness of the drones, combined with spectral precision, enable:
New Alzheimer’s medications require precise, regular monitoring. Hyperspectral technologies can provide valuable insights here—particularly regarding metabolic activity and therapy effectiveness.
Traditional diagnostic methods such as PET scans or cerebrospinal fluid tests are expensive, invasive, or difficult to access. A lumbar puncture is not only technically demanding but also painful—one reason many people avoid it.
This is exactly where the combination of Cubert’s snapshot hyperspectral technology and RetiSpec’s AI-based analysis comes into play.
The Retina: A Window Into the Brain
The retina itself is not the biomarker; rather, it contains numerous biomarkers. As part of the central nervous system, it is directly connected to the brain. A retinal scan therefore provides a unique opportunity to observe brain-related changes in a non-invasive way.
Studies show that retinal changes often occur long before the first symptoms of Alzheimer’s appear, including:
A partner study conducted by RetiSpec has already demonstrated over 90% specificity in detecting these changes—a strong indicator of the technology’s clinical potential.
The retina is therefore particularly well-suited for Alzheimer’s screening: easily accessible, non-invasive, and free of radiation exposure.
Hyperspectral Imaging: What Makes Cubert’s Technology Unique?
Cubert is a leading company in snapshot hyperspectral technology. For eye-related measurements, this technology is crucial—every millisecond counts. Key advantages include:
Snapshot Instead of Scanning
While traditional hyperspectral cameras scan pixel by pixel, Cubert’s snapshot cameras capture the entire scene in a single moment.
This eliminates motion artifacts—a major benefit, as even minimal eye movements can distort results.
120–130 Spectral Channels per Capture
Each pixel contains a full spectrum. This creates a complete 3D data cube captured in just milliseconds.
For patients, this means:
No long scanning times, no tedious fixation—just a few quick flashes and the measurement is done.
The Challenge: Identifying the Right Spectra
The AI models have been optimized over many years. Their goal: detect specific spectral patterns that indicate Alzheimer’s.
Optics experts and AI teams work closely together to achieve this.
Important to note:
Cubert delivers the data—medical professionals make the diagnosis.
In addition to visual spectra, the technology can capture information such as oxygenation levels.
How AI Detects Alzheimer’s Risk From Spectral Data
The hyperspectral datasets are analyzed using convolutional neural networks (CNNs). These algorithms:
Thanks to the enormous information density, molecular changes become visible that traditional imaging methods cannot detect.
Study Results: High Accuracy for AD and MCI Detection
Findings from studies using Cubert cameras and RetiSpec algorithms are promising:
Study 1: Alzheimer’s vs. Control Group (108 participants)
An earlier RetiSpec study demonstrated >90% specificity, forming the basis of an ongoing FDA approval process.
Study 2: Early Detection of Mild Cognitive Impairment (120 participants)
Additional data from the large Bio-Hermes-001 and -002 studies—comparing blood, digital, and PET biomarkers—further refine the role of the retina.
Accuracy is now approaching that of established diagnostic methods—without their disadvantages.
From Research to Everyday Clinical Use
Cubert and RetiSpec have worked together for more than seven years and have already installed over a dozen cameras in studies and pilot projects.
Their goal:
A fully integrated, turnkey ophthalmoscope that can be used as a new standard screening tool in
Support comes from:
Their vision:
Annual Alzheimer’s screenings could become as routine as checking blood pressure.
Advantages at a Glance
Conclusion: Alzheimer’s Could Soon Be Detected During a Simple Eye Exam
The combination of Cubert’s snapshot technology and RetiSpec’s AI opens an entirely new path for early Alzheimer’s detection: precise, non-invasive, and easily embedded into everyday clinical care.
What is now cutting-edge research may soon become a routine part of every eye exam—fundamentally transforming the diagnosis of one of the most common neurodegenerative diseases.
About the Author
Dr. René Heine is the Co-Founder and CEO of Cubert GmbH, a leader in real-time spectral imaging. Since founding the company in 2012, René has been instrumental in shaping Cubert’s technological direction and growth. He holds a Doctor of Physics degree from the University of Ulm, where he graduated magna cum laude, and completed his diploma thesis at Harvard Medical School. René’s deep expertise in physics and his vision for cutting-edge imaging technologies drive Cubert’s innovations and advancements in hyperspectral solutions.
